Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zai Lab (ZLAB) Asset Writedowns and Impairment (2020 - 2025)

Historic Asset Writedowns and Impairment for Zai Lab (ZLAB) over the last 6 years, with Q3 2025 value amounting to $625000.0.

  • Zai Lab's Asset Writedowns and Impairment rose 97758.62% to $625000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $920000.0, marking a year-over-year decrease of 1162.34%. This contributed to the annual value of $815000.0 for FY2024, which is 1623.84% down from last year.
  • Zai Lab's Asset Writedowns and Impairment amounted to $625000.0 in Q3 2025, which was up 97758.62% from $267000.0 recorded in Q2 2025.
  • In the past 5 years, Zai Lab's Asset Writedowns and Impairment ranged from a high of $966000.0 in Q4 2021 and a low of -$3000.0 during Q4 2022
  • Moreover, its 5-year median value for Asset Writedowns and Impairment was $138000.0 (2022), whereas its average is $239578.9.
  • In the last 5 years, Zai Lab's Asset Writedowns and Impairment crashed by 10031.06% in 2022 and then soared by 766666.67% in 2023.
  • Zai Lab's Asset Writedowns and Impairment (Quarter) stood at $966000.0 in 2021, then tumbled by 100.31% to -$3000.0 in 2022, then surged by 7666.67% to $227000.0 in 2023, then tumbled by 99.56% to $1000.0 in 2024, then surged by 62400.0% to $625000.0 in 2025.
  • Its Asset Writedowns and Impairment was $625000.0 in Q3 2025, compared to $267000.0 in Q2 2025 and $27000.0 in Q1 2025.